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Four-coordinate (Pt(II)) platinum-based anticancer drugs are widely used in primary or palliative chemotherapy and produce
considerable efficacy in certain clinical applications, for example testicular cancer. However, in many cancers the Pt(II) drugs are beset
by poor efficacy mainly due to suboptimal pharmacokinetic properties. Consequently, the six-coordinate (Pt(IV)) class of Pt drugs
were developed to improve platinum efficacy by (i) increasing stability, (ii) reducing reactivity, (iii) increasing lipophilicity, and (iv)
nuclear targeting. However, comparatively little information is available on the pharmacokinetic properties of these compounds
within solid tumour tissue. In the present study, the distribution and fluxes of [
14C]-labelled [PtCl2(en)] (where en stands for ethane-
1,2-diamine) and cis,trans-[PtCl2(OH)2(en)] drugs were determined in the multicell layer (MCL) tumour model comprising colon
cancer cells. Flux data were analysed by mathematical modelling of drug diffusion and cellular uptake in the transport system. The flux
of the Pt(IV) compound through the MCL was not significantly different to that of the Pt(II) drug nor were the diffusion coefficient or
tissue uptake; the latter confirmed with elemental imaging analysis by synchrotron radiation induced X-ray emission. However, the
flux of the Pt(IV) through the MCL was increased by hydrostatic pressure, thereby demonstrating the potential to target cancer cells
further away from the vessels with six-coordinate platinum drugs.
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Platinum drug complexes have been in clinical use for three
decades and their greatest curative potential is exhibited towards
certain subtypes of testicular cancer. The Pt complexes are widely
used in cancer chemotherapy but unfortunately their efficacy is
limited against the majority of malignancies. The reasons for the
failure of this important class of chemotherapeutic agent are a
combination of cellular drug resistance, toxicity and poor whole-
body or cellular pharmacokinetic profiles (Wang and Lippard,
2005). Cellular resistance to Pt drugs is largely attributed to
upregulation of DNA repair pathways, low intracellular accumula-
tion and inactivation by thiol-containing reductants such as
glutathione and metallothionein. Toxicity of cisplatin and its
four-coordinate derivatives is due to inherently high reactivity,
which leads to premature adduct formation with nucleophilic
groups on macromolecules (Kartalou and Essigmann, 2001). The
reactivity results from ‘aquation’ caused by the exchange of Cl
 
moieties for OH
  in a low chloride environment, such as that in
the intracellular milieu. The activation will ultimately manifest as
the side-effect profile in addition to ensuring that only a minor
fraction of the plasma platinum dose will be available to form
adducts with the DNA (Lindauer and Holler, 1996). Platinum can
exist in the oxidation states II and IV, and the presence of axial
ligands in the six-coordinate Pt(IV) complexes has generated a
series of compounds with considerably lower ‘aquation’ rates
(Dolman et al, 2002). The resultant increased stability and reduced
covalent binding to serum proteins (Dolman et al, 2002), facilitates
delivery of Pt(IV) drug to cancer cells at effective concentrations.
The efficacy of Pt(II) complexes is severely limited due to poor
cellular uptake. The main pathway for intracellular accumulation
of Pt drugs is thought to be passive diffusion through the plasma
membrane (Siddik, 2002), although the Ctr1 copper importer
(Holzer et al, 2004) and the copper export pump ATP7B (Katano
et al, 2004) have also been implicated. The introduction of
hydrophobic axial ligands in Pt(IV) complexes was thought to
provide a strategy to facilitate passive diffusion into cancer cells.
Unfortunately, the correlation between lipophilicity and cellular
uptake was weak for Pt(IV) compounds (Hall et al, 2004a),
although among a range of Pt(IV) compounds cis,trans-[PtCl2
(OH)2(en)] (where en stands for ethane-1,2-diamine) was the least
lipophilic (logPoct:  2.78) and had the lowest cellular uptake. In
contrast, there was a better correlation between the redox potential
and uptake of these compounds. This finding has generated a
model, which proposes that the Pt(IV) drug exists in a dynamic
equilibrium across the cell membrane and that the preferable rate
of intracellular ‘aquation’ and subsequent reactivity effectively
traps the drug inside the cell (Hall et al, 2004b).
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sDespite the many advantageous features of Pt(IV) complexes
that have been demonstrated in monolayer cultures of cancer cells,
few of this class of drug have entered clinical trials. A possible
explanation for this lack of translation may be the complexity of
solid tumours in vivo, relative to the in vitro experimental system.
Tumours in vivo represent complex three-dimensional cellular
organisations with a characteristically harsh microenvironment
comprising high cell density, low pH, toxic metabolites, low
oxygenation and elevated interstitial pressure. Few studies have
systematically examined the impact of these and other factors on
the efficacy of Pt(IV) complexes in solid tumours or provided
information on the distribution, diffusivity and flux of Pt(IV)
complexes through a solid tumour. It is known that the driving
force for passive diffusion through the plasma membrane is the
concentration gradient of the platinum compound. Hence
increased penetration of Pt(IV) complexes into tumour tissues, a
higher local drug concentration and rapid intracellular aquation
may significantly impact on the delivery of platinum compounds
to nuclear DNA. Given the complexity of tumour architecture
and biology there are many factors contributing to poor success;
penetration and uptake are the first such factors that need to be
overcome. Ensuring efficient delivery and uptake do not guarantee
efficacy, but without them, drug activity may be limited.
This investigation has examined the pharmacokinetic properties
of a reductively activated Pt(IV) compound in the multicell layer
(MCL) three-dimensional tumour model. This model, unlike the
more widely used tumour spheroid system, enabled a quantitative
analysis of the distribution and flux parameters for Pt drugs (Hicks
et al, 1997). The data verified a mathematical model developed to
describe drug pharmacokinetics within solid tissue. Moreover, a
novel elemental imaging analysis by synchrotron radiation
induced X-ray emission (SRIXE) was applied to examine Pt
distribution and the degree of intracellular accumulation in MCLs.
MATERIALS AND METHODS
Materials
Compounds [
14C]-[PtCl2(en)] ([
14C]-Pt(II); 34Ci/mol) (Figure 1B)
and [
14C]-cis,trans-[PtCl2(OH)2(en)] ([
14C]-Pt(IV); 6.8Ci/mol)
(Figure 1C) were synthesised according to published methods
(Hall et al, 2004b). Platinum compounds were dissolved in 100mM
KCl in ddH2O at 0.5mM concentration and stored in aliquots at
 201C. Twenty-four-well culture plates and Transwel-Col inserts
(polystyrene sidewall, 6.5mm internal diameter, bovine placental
collagen type I- and III-coated polytetrafluoroethylene (PTFE)
membrane, 0.33cm
2 surface, 400nm average pore size) were
obtained from Corning Life Sciences (Loughborough, UK),
penicillin and streptomycin from Cambrex Bioscience (Verviers,
France), spinner flasks were obtained from Techne Ltd (Cam-
bridge, UK). All other cell culture materials were purchased from
Invitrogen (Paisley, UK). Agarose was bought from BioWhittaker
Biological Applications (Rockland, ME, USA) and Ready Protein
þ
scintillation liquid from Beckman Coulter Inc. (Fullerton, CA,
USA). Hypoxyprobet-1 kit was purchased from Chemicon Europe
Ltd (Chandlers Ford, UK), Brij 35 from Fisher Scientific
(Loughborough, UK) and peroxidase blocking agent from DAKO
Corporation (Carpinteria, CA, USA). MACH2 horseradish per-
oxidase-labelled anti-mouse secondary antibody was obtained
from Biocare Medical (Concord, CA, USA) and DAB substrate
chromogen from DakoCytomation (Ely, UK). Haematoxylin and
Aquamount were purchased from BDH Laboratory Supplies
(Lutterworth, UK). All other chemicals were from Sigma and at
least analytical grade.
Cell lines and MCL culture
DLD1 colon carcinoma cells were a kind gift of Dr Roger Phillips
(Bradford, UK) and were maintained according to published
protocols (Hall et al, 2004b). DLD1 cell monolayers were detached
from culture flasks with trypsin/EDTA (Invitrogen) and 3 10
5
cells were seeded into Transwel-Col inserts. After a few hours the
cells settled and the inserts were transferred into spinner flasks
(Techne Ltd) with 50ml RPMI 1640 medium per insert and half of
the medium was refreshed every third day.
Measuring flux of radiolabelled compounds through the
MCL system
Triplicate inserts, with or without MCLs, were transferred into
24-well plates with 1000ml fresh medium in the wells (Figure 1A).
At the beginning of the transport assay the medium in the donor
compartment (DC) was replaced with fresh RPMI 1640 medium
containing the [
14C]-labelled platinum compound. The volume in
the DC was 150 and 1000ml in the RC. Under these conditions, the
fluid levels between the receiver compartment (RC) and DC were
level and consequently, transport was driven by the concentration
gradient. In subsequent experiments, to provide convective force
against the concentration gradient-driven diffusion, the volume of
the RC was increased to 1500ml. The reverse gradient was created
by increasing the DC volume to 280ml and keeping the RC at
1000ml. These two configurations provide 73mmH 2O hydrostatic
pressure between the two compartments. The RC was not stirred
because the flux rates across the membrane were identical with or
without stirring (data not shown). The experiment apparatus was
kept in the incubator (371C) and at each time point the insert was
moved to a new well. An 800ml sample was taken from the RC and
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Figure 1 The MCL system and chemical structures of platinum compounds. (A) Transwel-Col inserts were placed with MCL grown on the PTFE
membrane into the well of a 24-well tissue culture plate. The culture medium containing the radiolabelled compounds was added to the DC in variable fluid
volumes (I–III) and fluxes were measured by taking samples from the RC. (B and C) The structures of the four (B;[
14C]-cis-[PtCl2(en)]) and six-coordinate
platinum compounds (C;[
14C]-cis,trans-[PtCl2(OH)2(en)]). *Position of the
14Carbon radioisotopes. (D) The DLD1 MCL were cultured in spinner flasks for
16 days and stained with the hypoxia probe pimonidazole on a 5mm paraffin cross-sections ( 10 objective) (for details see Materials and Methods).
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sthe radioactivity at each time point was measured in a Beckman
liquid scintillation counter after mixing the sample with 4ml
Ready Protein
þ scintillation liquid.
Non-specific binding of radiolabelled compounds to the
transport apparatus can influence the interpretation of transport
results. Consequently, non-specific binding to polystyrene surfaces
in the RC was determined by measuring the decrease in drug
concentration within the compartment following 2h incubation
with [
14C]-Pt complex. The [
14C]-Pt complex was added as a 9:1
mixture of non-labelled and radiolabelled complexes in culture
medium at the concentration used during the transport assays.
The cumulative amount of drug in the RC was corrected for
non-specific binding to the RC.
A similar correction was made for drug concentrations in the
DC. After completion of transport assays, samples were taken from
the DC and the PTFE membranes with the MCL were excised to
measure bound radioactivity. In control experiments without
MCLs the PFTE membrane was excised. The percentage of added
[
14C]-Pt complex bound to the DC was determined by subtracting
the percentage bound to PTFE membrane in the presence or
absence of the MCL, the percentage transported to the RC and
from the percentage decrease in the DC at the end of the transport
assay.
SRIXE of MCL cross-sections
MCLs were harvested at the end of the transport experiment using
the Pt(IV) compound, processed as described (Modok et al, 2006),
and 20mm sections were cut from the paraffin blocks. The sections
were mounted on Formvar-coated plastic specimen holders.
Micro-SRIXE experiments were performed on beamline ID22 at
the European Synchrotron Radiation Facility (ESRF; Grenoble,
France). Fluorescence spectra were collected using a single element
Si(Li) detector, placed approximately 20mm from the sample.
Two-dimensional maps corresponding to the integrated Ka
fluorescence signal of an element of interest were collected by
scanning the sample. The elements analysed were P, S, Cl, K, Ca,
Fe, Ni, Cu, Zn, and Pt which was analysed using the La and Lb
fluorescence lines. Elemental contents were quantified by compar-
ison to the SRM 1832 and 1833 thin polymer film standards (NBS/
NIST, Gaithersburg, MD, USA) using the assumption for a thin
film target. Sectioned MCLs were analysed using a 13keV
monochromatic X-ray beam focused to a 1.8mm 4.5mm (verti-
cal horizontal) spot. Samples were mounted and suitable areas of
the MCL located by viewing the sample with a video-zoom
microscope. Scan areas were chosen so as to incorporate a
representative cross-section of the MCL. PyMca, an ESRF code,
was used for fitting the acquired spectra (http://www.esrf.fr/
computing/bliss/downloads/pymca/PyMCA.pdf). This allowed the
background contribution to be removed, facilitated analysis of
overlapping peaks, and accounted for the eventual escape peaks.
X-ray lines were fitted using the Hypermet function and a model
for background fitting was chosen as a tenth order polynomial for
an exponential background model. Computed X-ray line inten-
sities were normalised to the value of the incident photon flux.
Data analysis was performed by choosing regions of interest
(ROIs) within each scan. Such ROIs typically included one ROI
encompassing the majority of the scan area (‘whole MCL’), another
encompassing the free surface of the tissue (i.e. DC surface), and
another encompassing part of the PTFE membrane (i.e. RC
surface). The average fluorescence spectra from each ROI were
fitted using the PyMca X-ray fluorescence fitting program.
Elemental concentrations (mgcm
 2) were calculated from peak
areas using peak area:concentration ratios determined from NIST
thin-film standards (SRM 1832 and 1833), and then converted to
mgcm
 3 by accounting for the known section thicknesses. Such
calculations neglected secondary fluorescence processes and
assumed that the standards and the sample were similar to one
another. The Pt-La fluorescence line was used to quantify platinum
content in a similar fashion to that outlined by Ilinski et al
(2003) using fluorescence line cross-sections (at 13keV) of
Zn-Ka¼43.089cm
2g
 1, and Pt-La¼18.208cm
2g
 1 (Brunetti
et al, 2004). Elemental content of ROIs were compared to that of
the ‘whole MCL’ ROI, and the zinc content of the ROI.
Detection of hypoxia in MCL
Multicell layers were incubated with 200mM pimonidazole
(Hypoxyprobe-1) in culture medium for 2h and then fixed in
4% buffered paraformaldehyde. The fixed MCLs were extracted
and embedded in 4% agarose as described previously (Modok
et al, 2006). Multicell layers in agarose moulds were dehydrated
through routine histological processing and embedded in paraffin
for subsequent sectioning (5mm). Sections were de-waxed and the
pimonidazole detected with the Hydroxyprobe-1 monoclonal
antibody and the MACH2 secondary antibody as described
previously (Mellor et al, 2005).
Mathematical model to describe intra-MCL drug
pharmacokinetics
Model to describe drug flux through Transwel-Col mem-
branes The experimental system is depicted in Figure 1A and is
modelled as a closed system with mass conservation:
VDCD0 ¼ VDCDðtÞþVRCRðtÞð 1Þ
where VD and VR are the volumes of the DC and RC (ml),
respectively, and CDo is the initial concentration of the radio-
labelled compound in the donor chamber (nM), whereas
CB(0)¼0n M. The flux through the membrane is proportional to
the membrane surface area (A,c m
2) and the concentration
gradient across the membrane. Furthermore, the flux through
the membrane equals the change of concentration of molecules in
the RC, hence we get
d
dt
CRðtÞ¼
Ak
VR
ðCDðtÞ CRðtÞÞ ð2Þ
where k is the mass transfer coefficient (cms
 1). CD can be
eliminated using Eq. 1 and then Eq. 2 solved to give
CRðtÞ¼
VDCD0
VR þ VD
1   e
  Ak
VR
VR
VDþ1
  
t
 !
ð3Þ
The fitted parameter was k and the relative porosity of the
membrane for the compounds (Bimpedance, c) was determined
according to
k ¼
D1c
Dx
ð4Þ
where D1 is the diffusion coefficient of the compound in medium
(cm
2s
 1) and Dx is the measured thickness of the membrane (cm).
Mathematical model to describe flux of drugs through the
MCL The transport of radiolabelled compounds through the
MCL was modelled as Fickian diffusion. The insert with the
MCL can be seen as an anisotropic cylinder which has its axis
along the direction x (Figure 1A) and is bounded by planes
perpendicular to x and the problem of diffusion into it reduces to
the corresponding problem in an isotropic cylinder provided
Dy¼Dz, where Dy and Dz are diffusion constants in the other two
directions of space (Dolman et al, 2002). As the concentration only
varies along the x axis, we can describe the diffusion of the drug in
the MCL by
qC
qt
¼
q
qx
DM
qC
qx
  
ð5Þ
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swhere DM is the diffusion coefficient of the compound in the MCL
(cm
2s
 1) and x is the distance from the top free surface of the
MCL (cm), and g (s
 1) is the rate of cellular uptake of the
compound. DM can be defined by the impedance of MCL (G) and
the diffusivity of the compound in medium (D1,c m
2s
 1)a s
DM ¼ G   D1 ð6Þ
The boundary conditions were at x ¼ 0C 0;t ðÞ ¼ CDðtÞ, where the
concentration in top compartment is calculated from the mass
balance by considering the flux of molecules that enters the MCL,
i.e.,
d
dt
CDðtÞ¼
AD
VD
qC
qx
       
x¼0
withinitialconditionCDðt ¼ 0Þ¼CD0 ð7Þ
The continuity of the flux at the interface between the MCL and the
membrane gives us another boundary condition at
x ¼ xM   DM
q
qx
CðxM; tÞ¼kðCðxM;tÞ CRðtÞÞ ð8Þ
where xM is the thickness of the MCL. Furthermore, the governing
equation for the drug concentration in the RC (CR(t)) is at
x ¼ xM þ Dx
d
dt
CRðtÞ¼
Ak
VR
ðCðxR;tÞ CRðtÞÞ ð9Þ
Eqs. 5–9 are coupled partial differential equations, which were
used to write a program in Matlab to simulate the experimental
situation with initial conditions C¼0a t0 oxpxM and CR(0)¼0
to calculate G, DM and g.
Data analysis
Data were presented as either mean7s.d. or mean7s.e.m. The
data were analysed with two-tailed t-test using GraphPad Prism
3.2 software and Po0.05 was considered statistically significant.
Diffusivity and the rate of cellular uptake were determined using
programs based on the mathematical models described above and
written in Matlab 7.0.1 software.
RESULTS
Growth and histological characterisation of MCL
Multicell layers were cultured from DLD1 colon adenocarcinoma
cells on collagen-coated PTFE membranes (Figure 1), which were
floated in spinner flasks to provide optimised conditions for
growth. The MCL were used on the seventh day of culture and
displayed a tissue depth of 131710mm. A pimonidazole-based
assay was used to detect hypoxia in the MCL and demonstrate
tissue morphology (Figure 1D). Full morphological characterisa-
tion of this tissue model was described previously (Modok et al,
2006). The MCL showed pimonidazole staining towards the upper
surface of the tissue, which is indicative of hypoxia. This localised
hypoxia may be explained by the high demand for oxygen, which
results from such a densely packed avascular population of cells,
akin to that in tumour spheroids. This suggests that the MCL
model is a good representation of solid tumour architecture and
the associated microenvironment (Modok et al, 2006).
Diffusivity and cellular uptake rate of [
14C]-Pt(II) and
[
14C]-Pt(IV) compounds in MCL
The transport of the compounds through the PTFE membrane with
or without the MCL was measured by loading the radiolabelled
drugs to the DC and measuring the radioactivity appearing in the
RC over time (Figure 1A). Initially, 150 and 1000ml volumes
of culture medium were loaded to the DC and RC respectively, to
maintain an equivalent fluid level and therefore avoid hydrostatic
pressure-driven convective transport. The non-specific binding of
the compounds to the plastic surfaces in DC and RC was
determined to improve the accuracy of the subsequent quantitative
analyses (Table 1). For example, the fraction bound to the DC
reduces the effective concentration gradient, whereas the fraction
bound to the RC falsely reduces the flux rate. The fractions bound
to the DC and to the RC were used to correct the starting drug
concentration and the concentration of the drug transported,
respectively. The cumulative concentration of [
14C]-Pt(II) and
[
14C]-Pt(IV) were expressed as a percentage of the initial drug
concentration in the DC.
Figure 2 shows the cumulative amounts of Pt complexes
appearing in the DC of the MCL apparatus. Data are provided
for fluxes in the presence or absence of the MCL tissue overlaid on
the PTFE membrane. As expected, the rate and extent of flux was
greater for both drugs in the absence of the MCL. The data in
Figure 2 clearly demonstrates that there was no difference between
[
14C]-Pt(IV) and [
14C]-Pt(II) with respect to their cumulative
appearance in the DC. Mathematical modelling without a cellular
uptake parameter did not fit the data obtained in the presence of
an MCL, but was an accurate reflection for passage across the PTFE
membrane alone. The mathematical model comprising an uptake
coefficient was used to quantify flux of the compounds through
the solid tumour model and the data are summarised in Table 2.
The mass transfer coefficients (k) and relative porosity (c) values
Table 1 Binding of the radiolabelled compounds in the MCL system
Membrane MCL
%, mean7s.d. [
14C]-Pt(II) [
14C]-Pt(IV) [
14C]-Pt(II) [
14C]-Pt(IV)
Added to DC 100 100 100 100
Decrease in DC
a 46.372.6, n¼3 43.0672.6, n¼3 17.673.6, n¼12 15.374.1, n¼12
Membrane7MCL
b 0.170.1, n¼3 0.370.1, n¼5 0.770.3*, n¼6 0.570.2*, n¼9
Transported
c 27.875.0, n¼3 28.673.5, n¼3 5.370.8, n¼12 5.370.5, n¼12
Bound to RC
d 12.870.4, n¼3 16.671.2, n¼3 12.870.4, n¼3 16.671.2, n¼3
Bound to DC
e 18.577.0, n¼3 13.975.6, n¼3 10.172.8, n¼6 10.574.3, n¼9
Abbreviations: DC, donor chamber; en, ethane-1,2-diamine; MCL, multicell layer; [
14C]-Pt(II), [
14C]-[PtCl2(en)]; [
14C]-Pt(IV), [
14C]-cis,trans-[PtCl2(OH)2(en)]. The percentage
bound to the DC
e was calculated by subtracting the percentage bound to membrane7MCL
b and the percentage transported to the receiver chamber RC
c from the percentage
decrease in the DC
a at the end of the transport assay. These values and the non-specific binding of radiolabelled compounds to the RC
d were measured as it is described in
Materials and Methods. *Statistically significant (Po0.5) accumulation of the Pt compounds in the MCL compared to the PTFE membrane alone.
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sof the two platinum compounds through MCLs were indistin-
guishable. The coefficient of diffusion was ascertained for the
Pt(IV) and Pt(II) drugs through the MCL model utilising the
parameters of mass transfer coefficient (k), MCL thickness (xM),
diffusivity in the medium (D1) and initial drug concentration (CD).
The calculated diffusion coefficients (DM) and cellular uptake (g)
rates were not different for the two platinum compounds (Table 2),
reflecting similar flux parameters for the two classes of platinum
complex in a solid tissue.
Cellular accumulation of [
14C]-Pt in the MCL; SRIXE
analysis
Accumulation of Pt compounds in the MCL was determined by
measuring the radioactivity retained in the PTFE membra-
ne7MCL after the transport assays. As shown in Table 1, the
radioactivity associated with the membrane was higher in the
presence of the MCL, although there was no significant difference
between [
14C]-Pt(II) compared to [
14C]-Pt(IV). Data from the
mathematical modelling above suggested a significant degree of
uptake for Pt drugs within the MCL tissue. Image analysis using
SRIXE was used to confirm this suggestion and the technique
enabled an extensive elemental analysis of the MCL tissue. The
data show that the tissue that had been exposed to the [
14C]-Pt(IV)
drug was associated with an incorporated Pt signal (Figure 3). This
confirmed the experimental and mathematical modelling data and
demonstrates that flux through solid tissue is associated with a
non-negligible degree of Pt drug uptake into cells. Quantitation of
the Pt signal across the tissue revealed a greater Pt(IV) complex
concentration at the upper surface (i.e. facing the DC) (Figure 4).
The effect of hydrostatic pressure on the flux of
[
14C]-Pt(IV) through MCL
The six-coordinate Pt(IV) compounds have been proposed to
display a greater likelihood of reduction to the active Pt(II) species
in the hostile intratumour microenvironment. Consequently,
ensuring sufficient penetration of Pt(IV) drugs to the deeper
layers of a tumour remains a key issue. One proposed way of
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Figure 2 Flux kinetics of [
14C]-Pt(II) and [
14C]-Pt(IV) through MCL.
Typically, concentrations of 6mM [
14C]-Pt(II) (K) and 18mM [
14C]-Pt(IV)
(J) were administered to the DC. Appearance of radiolabelled
compound in the RC was measured as described in Materials and
Methods. The cumulative concentration in the CR (CR) was divided by the
starting concentration in the DC (CD) and plotted as the mean7s.d.
percentage of three independent experiments. The curves were fitted
using the mathematical models with (þ) or without ( ) terms for cellular
uptake as described in the Materials and Methods. Flux was measured
through (A) the PFTE membrane only and (B) MCL grown on the PFTE
membrane.
Table 2 Physical and chemical parameters of radiolabelled platinum
compounds
[
14C]-Pt(II) [
14C]-Pt(IV)
Molecular weight 325 359
Molecular radius (nm) 0.4
a 0.4
a
Diffusion coefficient in medium (D1,
 10
 6cm
2s
 1)
8.2
b 8.2
b
Mass transfer coefficient (k,  10
 5cms
 1) 2.770.6, n¼3 2.570.4, n¼3
Relative porosity of membrane (c;  10
 2) 1.270.3, n¼3 1.270.2, n¼3
Impedance of MCL (G; *10
 2) 2.170.3, n¼3 2.270.4, n¼4
Diffusion coefficient in MCL (DM;
 10
 8cm
2s
 1)
17.572.6, n¼317.873.1, n¼4
Uptake rate in MCL, (g;  10
 2min
 1) 17.775.5, n¼316.275.3, n¼4
aThe molecular radius of Pt(II) and Pt(IV) was estimated based on the size of
carboplatin (8 4 3A ˚) and cisplatin (5 3 1.5A ˚) as measured in MDLChime.
bThe diffusion coefficient of platinum compounds in culture medium was calculated
according to the Stokes–Einstein equation using the molecular radius.
Control
Zn
Ptl
Pt(II)
Figure 3 The cellular accumulation of [
14C]-Pt(IV) in MCL: SRIXE
analysis. After the transport assay the MCL was processed, embedded in
wax and 20mm sections through the MCL were imaged in a synchrotron
x-ray beam using SRIXE. Fitted images of the elemental distributions in
segments of a Pt(IV)-treated MCL and a control non-treated MCL are
shown. The scale on the axes represents the number of pixels, where each
pixel is 3 2mm (horizontal x vertical). The images show relative elemental
concentrations, using the colour scale shown, which ranges from blue,
representing low levels, to red, representing high elemental levels. The
arrowheads indicate the position of the PTFE membrane supporting the
MCL (shown in Figure 1D).
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simproving penetration is to increase the hydrostatic pressure to
counteract the increased interstitial pressure generated in
tumours. The MCL system (Figure 1) provides a convenient
means to investigate whether hydrostatic pressure can modulate
the flux of [
14C]-Pt(IV) through solid tumour tissue. Hydrostatic
pressure may be varied by simply altering the fluid levels in the DC
and RC and was applied in both the same and opposite directions
to the concentration gradient of the MCL system. Figure 5 shows
the cumulative amount of [
14C]-Pt(IV) that had penetrated
through the MCL in to the lower RC, relative to the amount of
drug added originally to the DC. At a hydrostatic pressure of
 3mm H 2O (i.e. against concentration gradient), the amount of
penetration was reduced from 0.8270.01 to 0.7370.01%. In
contrast, as the hydrostatic pressure was increased to þ4mmH 2O
(i.e. along the concentration gradient), the flux of [
14C]-Pt(IV) was
increased to 1.0670.08%. The data therefore indicate that even a
relatively minor hydrostatic pressure gradient was capable of a
significant influence on the flux of [
14C]-Pt(IV) through the MCL
tumour model.
DISCUSSION
Platinum-based chemotherapy remains a vital component of many
oncological treatment strategies. As with the majority of ‘geno-
toxic’ anticancer drugs, the Pt complexes are beset by problems
with toxicity, resistance and poor pharmacokinetic properties. A
great deal of effort has been placed in generating more potent and
selective derivatives of conventional Pt(II) drugs such as cisplatin.
In particular, the six-coordinate Pt(IV) complexes offer several
advantages including lower reactivity and a greater potential for
introducing hydrophobicity to facilitate cellular uptake. There is
little information available on either class of Pt drug relating to
their behaviour in solid tumour tissue. This study has utilised a
solid tumour model to quantify flux behaviour of Pt(II) and Pt(IV)
complexes. Flux through the solid tumour model was associated
with significant cellular accumulation and was sensitive to changes
in the applied hydrostatic pressure.
The MCL system is widely accepted as a good model of solid
tumour tissue, in particular the non-vascularised regions or
nodules. The colon cancer MCLs described previously (Modok
et al, 2006), display heterogeneity of cell status (i.e. proliferating
and quiescent) in addition to having a high cell density and
localised regions of hypoxia. Both of the compounds tested
were able to completely penetrate the MCL tissue with the
diffusion coefficients of 17.572.6 10
 8cm
2s
 1 for the Pt(II)
and 17.873.1 10
 8cm
2s
 1 for the Pt(IV) complex. These rates of
diffusion were almost 10-fold higher than that reported for the
hydrophobic anticancer drug vinblastine (1.8870.21 
10
 8cm
2s
 1) and fourfold higher than that of the highly
hydrophilic sucrose (4.2270.89 10
 8cm
2s
 1) (Modok et al,
2006). A similar rapid flux (i.e. % drugmin
 1) of cisplatin
compared to vinblastine has been reported in MCL comprising
bladder cancer cells, whereas etoposide, gemcitabine and paclitaxel
displayed faster rates of flux (Tannock et al, 2002). A major
advantage of the current approach is the ability to calculate the
actual diffusion coefficients, which may be directly applied to the
prediction of tissue drug concentrations; for example, as a function
of the distance from a blood vessel (Modok et al, 2006). This rapid
flux across the MCL should be considered a positive feature for
such compounds. A considerable emphasis in the design of
platinum drugs has been placed on developing lipophilic drugs
that can assist in circumventing diminished cisplatin accumulation
in resistant cell lines; however, it may be that defeating unicellular
resistance may come at the expense of tissue penetration, and
therefore create the problem of multicellular resistance. It seems
that hydrophilic drugs such as those examined here allow for
excellent tissue penetration. If this feature can be coupled with a
more readily reducible Pt(IV) compound (the Pt(IV) compound
studied here is the most inert in a series studied), a drug with good
penetration and cytotoxic potential may be arrived at.
The Pt(IV) compound used in this study has been shown to
display lower cellular accumulation in well-oxygenated monolayers
of cancer cells (Hall et al, 2004a) and lower serum protein binding
compared to the Pt(II) parental derivative (Dolman et al, 2002).
Therefore Pt(IV) would be expected to display higher flux rates
across MCL than Pt(II); unless the compound is rapidly converted
into the parental Pt(II) version. The latter is highly unlikely given
that in cells treated with platinum(IV) complexes, 50% of a trans-
Pt(IV) dihydroxo complex remained oxidised 2h after incubation,
which corresponds to the longest time point in these experiments
(Hall et al, 2003). The two Pt compounds had undistinguishable
flux kinetics across the MCL and in both cases the mathematical
model required the inclusion of a specific component to account
for cellular uptake within the tissue. Similarly, the calculated
diffusion constants and cellular uptake rates also failed to detect
any pharmacokinetic differences between the two compounds.
What is the explanation for the similar rates of flux through the
solid tissue given the physico-chemical differences between Pt(II)
and Pt(IV) species? Certainly neither compound has reacted
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Figure 4 Quantification of the cellular accumulation of [
14C]-Pt(IV) in
MCL. The platinum contents of the surfaces exposed to the DC and the
RC were quantified and normalised relative to a region representative of
the entire MCL. Values are expressed as percentages, where a value of 100
is indicative of an elemental content identical to that of the whole MCL.
The data represent the mean and s.e. associated with two scans.
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Figure 5 The effect of hydrostatic pressure on flux kinetics in MCL.
Hydrostatic pressure was applied by varying the volume of medium added
to the DC and the RC as described in Materials and Methods. The flux
kinetics [
14C]-Pt(IV) were determined and the cumulative RC concentra-
tion relative to the diffusion only values are shown as mean7s.e.m. of at
least three independent experiments. *Statistically significant difference
(Po0.05).
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sextensively with growth media in the time examined. Perhaps the
cellular accumulation of [
14C]-Pt(IV) is limited by the lack of
reactivity, allowing passage through the MCL at a rate similar to
the more lipophilic Pt(II) complex. If the Pt(IV) compound was
more reactive and thus converted into the corresponding Pt(II)
compound, the concentration gradient into the cell for the Pt(IV)
would remain high enough to ensure greater uptake. Conse-
quently, future Pt(IV) development would require taking into
account both transbilayer diffusion and the intracellular reactivity.
In addition to allowing detailed flux analysis, the mathematical
model predicts that a concentration gradient would exist within
the MCL decreasing from the free surface of the tissue towards
the semiporous PTFE membrane (i.e. DC-RC direction) (Modok
et al, 2006). The SRIXE element array qualitatively demonstrated
that the distribution of the Pt(IV) compound was similar to that
predicted by the mathematical model, that is, more Pt was detected
close to the free surface of the MCL. This is the first report where
the distribution of drugs within the MCL was experimentally
verified and compared to the one predicted by mathematical
modelling. That more Pt was observed close to the upper surface of
the MCL is in keeping with previous observations with cisplatin
detected by antibody in squamous carcinoma cell spheroids, and a
Pt-porphyrin compound in J82 spheroids observed by fluorescence
microscopy, which inferred more intense drug signal (although
both relied on a molecular signature other than the active Pt centre
itself) at the periphery of spheroids (Nishikawa et al, 1990; Lottner
et al, 2004). In the case of the Pt-porphyrin complex, it took 24h
before uniform drug distribution could be achieved, although this
is not reflective of the drug distribution expected to be achieved by
a pulse of chemotherapeutic agent.
Most solid tumours have high interstitial pressures that slow
drug transit and filtration through tissue and consequently drug
movement in cancer tissue is largely limited to diffusion (Heldin
et al, 2004). Restoring the physiological filtration by increasing the
hydrostatic pressure is a possible option to improve drug delivery
to deeper layers of cancer cells within the three-dimensional solid
tumour mass. Our results show that because the flux of the two
compounds was sensitive to hydrostatic pressure the convection
could potentially increase the penetration of tumour mass by
platinum drugs. This principle, known as convection enhanced
delivery (CED), has actually been utilised to treat intracranial
tumours where the confined space further increases the effects of
interstitial pressure (Heldin et al, 2004). Cisplatin is expected to
be useful via local drug delivery (Newton, 2005) in intracranial
tumours due to its reported rapid flux rate, although an
enhancement by CED has not yet been examined.
In conclusion, the data from this investigation provide hitherto
unknown pharmacokinetic properties for two platinum com-
pounds; namely the absolute diffusion coefficient through solid
tumour tissue. Moreover, both experimental and mathematical
models provide a convenient means to facilitate the in vitro
development of novel six-coordinate platinum compounds;
particularly to enable a bridge between observations in simple
cell monolayer systems to the complexities associated with poorly
vascularised hypoxic tumours in vivo.
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